Celcuity’s (CELC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note published on Friday,Benzinga reports. The firm currently has a $27.00 price objective on the stock.

Several other brokerages also recently commented on CELC. Lifesci Capital assumed coverage on shares of Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Stifel Nicolaus raised their price objective on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Leerink Partners started coverage on Celcuity in a research note on Monday, July 22nd. They issued an “outperform” rating and a $29.00 target price for the company. Leerink Partnrs raised Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Celcuity in a research report on Friday. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $29.17.

Celcuity Price Performance

Shares of CELC opened at $12.66 on Friday. The stock has a market cap of $468.80 million, a P/E ratio of -4.85 and a beta of 0.76. Celcuity has a 1 year low of $11.51 and a 1 year high of $22.19. The stock’s 50-day moving average price is $15.15 and its two-hundred day moving average price is $16.04. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CELC. Quest Partners LLC boosted its position in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Celcuity by 9.9% in the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares during the last quarter. Acuta Capital Partners LLC grew its position in Celcuity by 3.6% in the third quarter. Acuta Capital Partners LLC now owns 46,600 shares of the company’s stock valued at $695,000 after purchasing an additional 1,600 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Celcuity in the 3rd quarter valued at $33,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.